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Rotavirus  gastroenteritis  is  one  of the  leading  causes  of diarrhea  in  Indian  children  less than  2 years  of
age. The  116E  rotavirus  strain  was  developed  as  part of  the  Indo-US  Vaccine  Action  Program  and  has
undergone  efﬁcacy  trials.  This  paper reports  the  efﬁcacy  and  additional  safety  data  in  children  up  to  2
years  of  age.
In  a  double-blind  placebo  controlled  multicenter  trial,  6799  infants  aged  6–7  weeks  were  randomized
to  receive  three  doses  of  an  oral  human-bovine  natural  reassortant  vaccine  (116E)  or placebo  at  ages  6,  10,
and  14  weeks.  The  primary  outcome  was  severe  (≥11 on  the  Vesikari  scale)  rotavirus  gastroenteritis.  Efﬁ-
cacy outcomes  and  adverse  events  were  ascertained  through  active  surveillance.  We  randomly  assigned
4532 and  2267  subjects  to receive  vaccine  and  placebo,  respectively,  with  over 96%  subjects  receiving  all
three  doses  of  the vaccine  or  placebo.  The  per  protocol  analyses  included  4354  subjects  in  the  vaccine
and  2187  subjects  in  the  placebo  group.  The  overall  incidence  of severe  RVGE  per 100  person  years  was
1.3  in  the  vaccine  group  and  2.9 in  the  placebo  recipients.  Vaccine  efﬁcacy  against  severe  rotavirus  gas-
troenteritis  in children  up  to  2 years  of age  was  55.1%  (95% CI 39.9 to 66.4;  p <  0.0001);  vaccine  efﬁcacy  in
the  second  year  of life  of  48.9%  (95%  CI 17.4  to 68.4;  p =  0.0056)  was  only  marginally  less than in the ﬁrst
year  of life  [56.3%  (95%  CI 36.7 to 69.9;  p < 0.0001)].  The  number  of  infants  needed  to  be  immunized  to
prevent  one  episode  of  severe  RVGE  in the  ﬁrst  2  years  of life  was  40 (95%  CI 28.0  to 63.0)  and  for  RVGE
of  any  severity,  it was  21 (95%  CI  16.0  to  32.0).  Serious  adverse  events  were  observed  at  the  same  rates  in
∗ Corresponding author at: Ministry of Science and Technology, Government of India, B-10, Soami Nagar, New Delhi 110017, India. Tel.: +91 11 41748476;
ax:  +91 11 41748476.
E-mail address: rajkbhan@gmail.com (M.K. Bhan).
1 Dr. Kohberger died in March 2012.
2 See Appendix A.
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the  two  groups.  None  of  the  eight  intussusception  events  occurred  within  30  days  of a  vaccine  dose  and
all  were  reported  only  after  the  third  dose.
The sustained  efﬁcacy  of the  116E  in  the  second  year  of  life is  reassuring.
Clinical  Trial  Registry:  The  trial is  registered  with  Clinical  Trial  Registry-India  (#  CTRI/2010/091/000102)
and  Clinicaltrials.gov  (# NCT01305109).
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. Introduction
Rotavirus continues to be one of the leading causes of diar-
hea in children under 5 years of age and is a particular problem
n India, which harbors almost one-fourth of the estimated num-
er of rotavirus deaths in the world [1]. Most cases of rotavirus
astroenteritis (RVGE) occur in children below 2 years of age [2].
n developing countries, most of the burden of rotavirus disease
ccurs in the ﬁrst year of life but there remains a substantial bur-
en in the second year of life as well [3,4]. As reported by the Indian
otavirus Surveillance Network, 36.5% and 38.9% of hospitalized
ases were rotavirus associated, in infants aged 6–11 months and
hildren aged 12–23 months respectively [5].
The 116E rotavirus vaccine was developed from a neonatal
uman rotavirus strain identiﬁed in India, as part of the Indo-US
accine Action Program [6]. The 116E rotavirus strain, G9P[11], is
 naturally occurring reassortant containing one bovine rotavirus
ene P[11] and ten human rotavirus genes [7,8]. The 116E vero cell
ased rotavirus vaccine was assessed for efﬁcacy against severe
otavirus gastroenteritis in a multi-center, randomized placebo
ontrolled trial in India and safety and efﬁcacy during the ﬁrst year
f follow up have recently been published [9].
We  now report the efﬁcacy and additional safety data for the
econd year of life and for the total follow-up until 2 years of age.
. Material and methods
.1. Study design and participants
A multi-center double blind placebo controlled phase III trial
as conducted at Delhi, Pune and Vellore in India between March
1, 2011 and September 26, 2013 [9]. The study was approved
y the site Ethics Committees, the Department of Biotechnology
India) and the Western Institutional Review Board (USA), and con-
ucted in compliance with the protocol, good clinical practices, and
ational regulatory and ethics guidelines. Informed written consent
as taken from parents at enrollment.
The detailed methods and study procedures have been previ-
usly described [9]. Brieﬂy, a total of 6799 infants were enrolled
nd randomly assigned in a 2:1 ratio to receive either the vac-
ine or placebo using the Interactive Voice Response System or
nteractive Web  Response System with a block size of 12. Enrolled
nfants were administered the 116E vaccine or placebo along with
he childhood vaccines (a pentavalent vaccine including Diphthe-
ia, Pertussis, Tetanus, Haemophilus inﬂuenzae b and Hepatitis B,
nd Oral Polio Vaccine) at 6, 10 and 14 weeks of age. Infants were
xcluded if they had received a rotavirus vaccine, if they had doc-
mented immunodeﬁciency, chronic gastroenteritis or any other
isorder that was deemed necessary for exclusion by the inves-
igator. Infants were temporarily excluded if they had any illness
eeding hospital referral or diarrhea on the day of enrollment.
The 116E vaccine or placebo was administered 5–10 min  after
dministration of 2.5 mL  of citrate bicarbonate buffer. Families
ere contacted weekly at home by trained ﬁeld workers for
scertaining efﬁcacy and safety outcomes. Trained ﬁeld workers
ollected information on characteristics of gastroenteritis episodes
or each day. A stool sample was collected for each episode ofElsevier  Ltd. This  is  an  open  access  article  under  the  CC BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
gastroenteritis. Mothers were provided mobile phones to ensure
easy access to study physicians, who were available round the
clock for management of illness. Medical care including trans-
portation and hospitalization were facilitated and paid for by the
study [9].
The primary outcome was the incidence of severe RVGE (≥11
on the Vesikari scale) [10]. The secondary outcomes being reported
include severe RVGE requiring hospitalization or supervised rehy-
dration therapy, very severe RVGE, RVGE of any severity and
others.
2.2. Stool sample analysis
Diarrheal stools were examined for rotavirus with a commercial
enzyme immunoassay (Premier Rotaclone, Meridian Bioscience,
USA). Rotaclone-positive stools were analyzed for G (VP7) and
P (VP4) genotypes by multiplex PCR [11,12]. If both were neg-
ative, a PCR assay for the VP6 gene was done to adjudicate
where the ELISA result was a false positive [13]. The genotyping
assay was  not designed to differentiate vaccine G9P[11] from wild
G9P[11].
Participants were assessed in detail for intussusception on the
basis of broad screening criteria decided a priori, described pre-
viously [9]. Children with one or more signs or symptoms of
the a priori criteria were examined by a pediatrician, referred
to a pediatric surgeon and admitted to hospital, as necessary.
An intususception case adjudication committee consisting of a
pediatric surgeon, a pediatrician, and a radiologist reviewed all
investigator-diagnosed cases of intussusception using the Brighton
criteria level 1 to provide the ﬁnal diagnosis [14].
2.3. Statistical analyses
Analyses were done by Quintiles using SAS® Version 9.2. Efﬁ-
cacy analysis is presented for the per-protocol (PP) population. The
PP population included all subjects who received the same treat-
ment for all three doses of vaccine orplacebo within the a priori
deﬁned windows and who reported episodes of diarrhea occur-
ring more than 14 days after the third dose. For each endpoint
within the three age windows (from more than 14 days after third
dose to the end of age 1 and 2 years and for age 1–2 year period),
only the ﬁrst event was counted for each subject. The follow up
period associated with each event was calculated as time to occur-
rence of that event or date of dropout or the date of completion of
follow up.
Efﬁcacy estimates for ﬁrst year of life include events that
occurred till one year of age and efﬁcacy for the second year
includes events occurring between 1 and 2 years. Vaccine efﬁcacy
was calculated as 100 × (1 − [nv/Fv]/[np/Fp]) person time incidence
rate, where nv and np were the number of subjects with at least one
episode in the relevant groups (vaccine or placebo) and Fv and Fp
are the total length of follow up in the relevant treatment group. p
values and conﬁdence intervals for vaccine efﬁcacy were computed
using exact binomial methods [15]. Efﬁcacy outcomes are also dis-
played as a forest plot of incidence rate ratios on a log scale in the
two groups. The time to event analysis by groups are presented as
Kaplan–Meier curves.
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.4. Role of funding sources
The Department of Biotechnology, and Biotechnology Indus-
ry Research Assistance Council, Government of India, New Delhi,
ndia; the Bill & Melinda Gates Foundation (#52714) to PATH, USA;
esearch Council of Norway; Department for International Devel-
pment, United Kingdom; National Institutes of Health, Bethesda,
SA; Bharat Biotech International Limited, Hyderabad, India pro-
ided funding. The funders had no inﬂuence on how the data was
ollected; analyses were done by Quintiles.
. Results
Of the 7848 infants screened, we enrolled 6799 subjects: 4532
ubjects received the vaccine and 2267 subjects the placebo. A total
f 4419 in the vaccine group and 2191 in the placebo group com-
leted follow up till 2 years of age. In the PP analyses, 4354 in the
accine group and 2187 in the placebo group were included for the
verall analyses (Fig. 1). The total follow up time in the PP pop-
lation was 7066.4 and 3482.3 years in the vaccine and placebo
roups, respectively.
The mean (SD) ages at the time of receiving dose one, two and
hree were 6.8 (0.6), 11.7 (2.4) and 16.3 (2.8) weeks respectively and
hese were similar in the vaccine and placebo groups. Compliance to
accine intake was high for subsequent doses; only 3.5% of infants
id not receive all the three intended doses.
.1. Vaccine efﬁcacy against severe gastroenteritis
Vaccine efﬁcacy in children up to 2 years of age was 55.1% (95%
I 39.9 to 66.4; p < 0.0001); the vaccine efﬁcacy in the second year
f life of 48.9 (95% CI 17.4 to 68.4; p = 0.0056) was  only marginally
ess than that in the ﬁrst year of life [56.3% (95% CI 36.7 to 69.9; < 0.0001)]. The results were similar in the intent-to-treat (ITT)
opulation where up to 2 years efﬁcacy of 55.8% (95% CI 41.3 to 66.7;
 < 0.0001) did not differ substantially from that in the ﬁrst [57.2%
95% CI 38.9 to 70.1; p < 0.0001)] or the second year of life at 49%roﬁle.
(95% CI 17.5 to 58.4; p = 0.0055). There was  no signiﬁcant interac-
tion of treatment group and site with vaccine efﬁcacy (p = 0.4802).
The secondary endpoint analyses strongly supported the pri-
mary analysis (Table 1). In the second year of life, the vaccine
efﬁcacy against RVGE of any severity requiring hospitalization or
supervised rehydration therapy, RVGE requiring hospitalization
≥6 h and severe GE of any etiology were 34.3% (95% CI 17.2 to 47.8),
35.9% (95% CI −9.1 to 62) and 10.9 (95% CI −17 to 31.8) respec-
tively. For the genotype speciﬁc analysis, there were a total of 199
episodes of severe RVGE that occurred in 195 subjects up to 2 years
of age. For this particular analysis, a subject could contribute more
than one primary event if associated with a different genotype. Four
subjects had more than one episode of severe RVGE with different
genotypes; three in the vaccine group and one in the placebo.
The most prevalent (85%) rotavirus genotypes identiﬁed in
the 199 episodes were G1P[8] (37%; n = 74), G2P[4] (31%; n = 61),
G12P[6] (11%; n = 21) and G12P[8] (7%; n = 13). A post hoc analyses
on the genotype speciﬁc efﬁcacy is consistent with the overall pro-
tective efﬁcacy. The G9P[4] genotype had an imbalance of cases
with nine in the vaccine group and one in the placebo group
(Table 2).
Survival curves in the vaccine group compared with the placebo
group showed a signiﬁcantly increased cumulative proportion of
infants without severe RVGE (Fig. 2). We  calculated that 40 infants
would need to be immunized to prevent one episode of severe RVGE
in the ﬁrst 2 years of life (95% CI 28.0 to 63.0) and 21 had to be
immunized to prevent RVGE of any severity in the same period
(95% CI 16.0 to 32.0).
Fig. 3 displays the incidence rate ratios for the primary outcome
and several secondary outcomes as a forest plot. In children up to
2 years of age, the incidence of severe RVGE per 100 person years
was 1.3 in the vaccine group and 2.9 in the placebo group for an
incidence rate ratio of 0.45 (95% CI 0.34 to 0.60) and an absolute
rate reduction of 1.6 (95% CI 0.9 to 2.2). In the ﬁrst year of life, the
incidence of severe RVGE per 100 years was  2.0 in the vaccine group
and 4.6 in the placebo group, an incidence rate ratio of 0.44 (95%
CI 0.30 to 0.63); in the second year of life it was 0.9 in the vaccine
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Table  1
Efﬁcacy of the vaccine in the prevention of gastroenteritis in children up to 2 years of age in the per protocol population.
Endpoints n Vaccine efﬁcacy % (95% CI) p value
VaccineN = 4354 PlaceboN = 2187
Severe RV GE
Till 2 years of age 93 (2%) 102 (5%) 55.1 (39.9 to 66.4) <0.0001
Till  1 year of age 57 (1%) 65 (3%) 56.3 (36.7 to 69.9) <0.0001
Between 1 and 2 years of agea 38 (<1%) 37 (2%) 48.9 (17.4 to 68.4) 0.0056
Severe RV GE requiring hospitalizationb or supervised rehydration therapyc
Till 2 years of age 92 (2%) 102 (5%) 55.6 (40.5 to 66.8) <0.0001
Till  1 year of age 57 (1%) 65 (3%) 56.3 (36.7 to 69.9) <0.0001
Between 1 and 2 years of agea 37 (<1%) 37 (2%) 50.2 (19.3 to 69.3) 0.0042
Very  severe RV GE
Till 2 years of age 12 (<1%) 14 (<1%) 57.2 (0.3 to 81.9) 0.0491
Till  1 year of age 9 (<1%) 9 (<1%) 49.8 (−42.6 to 82.4) 0.2176
Between 1 and 2 years of agea 3 (<1%) 5 (<1%) 70.1 (−53.9 to 95.4) 0.1750
RV  GE of any severity
Till 2 years of age 406 (9%) 310 (14%) 36.4 (26.0 to 45.3) <0.0001
Till  1 year of age 226 (5%) 172 (8%) 35.0 (20.2 to 46.9) <0.0001
Between 1 and 2 years of agea 194 (4%) 150 (7%) 36.2 (20.5 to 48.7) <0.0001
Data are n (%) unless otherwise indicated. We deﬁne severe gastroenteritis as episodes with a Vesikari score of 11 or greater. Episodes of severe rotavirus gastroenteritis had
a  Vesikari score of 11 or greater and presence of rotavirus (Rotaclone positive and VP6 or VP4 and VP7 positive by RT PCR) strains; includes all cases except those for which
G9P[11] was  isolated. Episodes of very severe gastroenteritis had a Vesikari score of 16 or greater.
a
g
(
3
c
d
i
O
p
s
FN in vaccine = 4339, placebo = 2177.
b Inpatient admission for at least 6 h in a treatment facility or hospital.
c Administration of oral rehydration salts or intravenous ﬂuids.
roup and 1.7 in the placebo group, an incidence rate ratio of 0.51
95% CI 0.32 to 0.83).
.1.1. Safety
Studies have reported adverse events immediately after vac-
ination and in the 2 week window following any of the three
oses [9]. We observed serious adverse events at the same rates
n the vaccine (20.9%, n = 947) and placebo group (22.7%, n = 515).
nly three subjects, one in the vaccine (urticaria) and two  in the
lacebo (acute gastroenteritis and suspected sepsis) group had a
erious adverse event (SAE) that was considered related to the
ig. 2. Kaplan–Meier survival curve for severe rotavirus gastroenteritis per protocol populvaccine. There were no statistically signiﬁcant differences in system
organ class and preferred terms as classiﬁed by MedDRA except for
rotavirus gastroenteritis which was lower in the vaccine group as
expected. There were 30 deaths in 4532 (0.7%) vaccine group and 18
in the 2267 (0.8%) placebo group and none were considered related
to the vaccine.
Intussusception by Brighton Level 1 criteria was  met  in 8 of the
4532 (0.2%) events occurring in vaccine group and 3 of the 2267
(0.1%) events occurring in the placebo group (p = 0.7613). None
occurred within 30 days of a vaccine dose and all were reported
only after the third dose. The intussuception events following the
ation: time 0 represents 15 days after receipt of the third dose of vaccine or placebo.
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Table  2
Efﬁcacy analysis for severe rotavirus gastroenteritis by genotype in per protocol
population up to 2 years of age.
VaccineN = 4354 PlaceboN = 2187 Vaccine efﬁcacy % (95% CI)
Alla 93 (2.1%) 102 (4.7%) 55.1% (39.9 to 66.4)
G1P[8] 40 (0.9%) 34 (1.6%) 42.0% (5.6 to 64.2)
G2P[4] 26 (0.6%) 35 (1.6%) 63.4% (37.4 to 78.8)
G12P[6] 8 (0.2%) 13 (0.6%) 69.7% (21.1 to 89.1)
G12P[8] 5 (0.1%) 8 (0.4%) 69.2% (−6.8 to 92.1)
G9P[4] 9 (0.2%) 1 (<0.1%) −343.5% (−19562 to 38.5)
Othersb 8 (0.2%) 12 (0.5%) 67.1% (12.6 to 88.4)
Data are n (%) unless otherwise indicated.
a Total number of subjects included in PP population is 195; 4 subjects had more
than 1 episode of severe non vaccine RV GE and therefore the total number of
e
G
t
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a
1
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s
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Rpisodes 199 is greater than the total number of subjects.
b Includes all genotypes causing seven cases or less (G9P[8], G1P[4], G1P[6],
2P[6], G1P[0], G0P[0], G9P[0], G12P[11]).
hird dose occurred between 112 and 587 days post vaccination
n the vaccine group and between 36 and 605 days in the placebo
roup.
. Discussion
The efﬁcacy of the 116E vaccine against the primary outcome,
evere RVGE, in the second year of life (48.9%) is only marginally
ower than the 56.3% reported in the ﬁrst year of life [9]. The ﬁndings
or the second year follow up from the ITT analyses support the PP
nalyses. The protection offered in the second year of life by the
16E vaccine increased with greater severity of clinical disease, just
s was seen in the ﬁrst year analyses [9].In developing countries, the point estimate for efﬁcacy against
evere RVGE during the ﬁrst 2 years of life for the 116E vaccine
s comparable to results reported for the two licensed vaccines,
otaTeq and Rotarix [16]. While the efﬁcacy of rotavirus vaccines
Severe RVGE upto  2 years
RVGE of an y severity upto 2 years
RVGE any severity requiring hospitali zation
Severe RVGE requiring hospitalization
RVGE requiring hospitali zation >= 6 hrs upto 2 years
Very severe RVGE upto 2 years
or supervised rehydration therapy upto 2 years
or supervised rehydration therapy upto 2 years
Severe RVGE until  1 year
Severe RVGE in 1-2 yea rs
.1 
Incidenc
Fig. 3. Forest plot of incidence rate ratio on log sca2S (2014) A110–A116
has been lower in the second than the ﬁrst year of life, the reduction
in efﬁcacy was substantially lower in some settings with licensed
vaccines [3,4,17,18]. In this regard, only a marginal decrease in
efﬁcacy of 116E in the second compared to the ﬁrst year of life
is reassuring. In the updated analyses for the ﬁrst 2 years of life,
SAEs, deaths and cases of intussusception were similar between
vaccine and placebo groups. A decisive assessment of the risk of
intussusception is to be carried out during phase IV post marketing
studies.
As noted previously, the 116E vaccine has an unusual G9P[11]
genotype that is rarely associated with clinical disease in India or
other countries. The protection offered by this vaccine during the
ﬁrst 2 years of life is against the array of commonly circulating
genotypes including G1P[8], G2P[4], G12P[6], G12P[8] and G9P[4].
This suggests that the vaccine could offer signiﬁcant protection in
varying geographical settings and over time. This ﬁnding also sup-
ports the view that there are multiple determinants that provide a
lead to protective immunity. We  noted an imbalance of cases asso-
ciated with G9P[4] but could not identify any biological basis for
this imbalance and conclude that this was due to chance alone.
The efﬁcacy of the licensed rotavirus vaccines is higher in devel-
oped than in developing countries [19–23]. Although the efﬁcacy
of 116E in the ﬁrst 2 years of life is modest as it is for other licensed
vaccines, the impact on preventing deaths related to severe RVGE is
likely to be high in India and other developing countries because of
the higher disease burden [2,4]. It is for this reason that the World
Health Organization has recommended inclusion of rotavirus vac-
cine into national immunization programs.
Finally, the development of 116E is a unique example of team
work and global collaboration and represents a novel approach
to development of affordable health technologies of particular
interest to developing countries [24]. Efforts are underway to
understand the reasons underlying the relatively modest efﬁcacy
of all live rotavirus vaccines in low middle income countries.
1 10 100
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